{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Brown CE"],"funding":["National Cancer Institute","NCI NIH HHS","National Institutes of Health","California Institute of Regenerative Medicine"],"pagination":["1318-1330"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9340633"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(8)"],"pubmed_abstract":["Background
Wide-spread application of chimeric antigen receptor (CAR) T cell therapy for cancer is limited by the current use of autologous CAR T cells necessitating the manufacture of individualized therapeutic products for each patient. To address this challenge, we have generated an off-the-shelf, allogeneic CAR T cell product for the treatment of glioblastoma (GBM), and present here the feasibility, safety, and therapeutic potential of this approach.Methods
We generated for clinical use a healthy-donor derived IL13Rα2-targeted CAR+ (IL13-zetakine+) cytolytic T-lymphocyte (CTL) product genetically engineered using zinc finger nucleases (ZFNs) to permanently disrupt the glucocorticoid receptor (GR) (GRm13Z40-2) and endow resistance to glucocorticoid treatment. In a phase "],"journal":["Neuro-oncology"],"pubmed_title":["Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma."],"pmcid":["PMC9340633"],"funding_grant_id":["R01CA254271","P30 CA033572","R01 CA236500","R01 CA254271","P30CA033572","CLIN2-10248","R01CA236500","R01CA155769","R01 CA155769"],"pubmed_authors":["Ostberg JR","Wagner JR","Holmes MC","Jensen MC","Naranjo A","Tran V","Weng L","Zhou Y","Rodriguez A","Forman SJ","Badie B","Brown CE","Starr R","Synold TW","Gregory PD","Tang WW","D'Apuzzo M","Wang S","Mendel M","Ressler JA","Aguilar B","Reik A","Palmer J"],"additional_accession":[]},"is_claimable":false,"name":"Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.","description":"Background
Wide-spread application of chimeric antigen receptor (CAR) T cell therapy for cancer is limited by the current use of autologous CAR T cells necessitating the manufacture of individualized therapeutic products for each patient. To address this challenge, we have generated an off-the-shelf, allogeneic CAR T cell product for the treatment of glioblastoma (GBM), and present here the feasibility, safety, and therapeutic potential of this approach.Methods
We generated for clinical use a healthy-donor derived IL13Rα2-targeted CAR+ (IL13-zetakine+) cytolytic T-lymphocyte (CTL) product genetically engineered using zinc finger nucleases (ZFNs) to permanently disrupt the glucocorticoid receptor (GR) (GRm13Z40-2) and endow resistance to glucocorticoid treatment. In a phase ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-09T22:21:52.169Z","creation":"2024-11-19T19:15:35.25Z"},"accession":"S-EPMC9340633","cross_references":{"pubmed":["35100373"],"doi":["10.1093/neuonc/noac024"]}}